MedTrace Logo

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244

NCT01635023 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-10-25

No results posted yet for this study

Summary

Study in Healthy Males to Compare the White and Blue Formulations of AZD6244.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD6244 Dosing Period 1

Treatment A, B, or C depending on randomization assignment

DRUG

AZD6244 Dosing Period 2

Treatment A, B, or C depending on randomization assignment

DRUG

AZD6244 Dosing Period 3

Treatment A, B, or C depending on randomization assignment

DRUG

AZD6244 Dosing Period 4

Treatment B

Sponsors & Collaborators

Principal Investigators

  • Ian Smith, MEDICAL SCIENCE DIRECTOR · AstraZeneca

  • Eleanor Lisbon, MD · Quintiles, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635023 on ClinicalTrials.gov